PFE

Pfizer Inc. Q1 2007 Financial Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended April 1, 2007. Pfizer Inc. is a global research-based pharmaceutical company. The reporting period reflects the company's transition following the December 2006 sale of its Consumer Healthcare business, which is now reported as discontinued operations. The company operates primarily through its Pharmaceutical and Animal Health segments.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 6% year-over-year, driven by a 5% increase in Pharmaceutical revenues and a 15% increase in Animal Health revenues. Growth was supported by new product launches (e.g., Lyrica, Sutent, Caduet) and favorable foreign exchange impacts ($269 million), partially offset by the loss of exclusivity for major products like Zoloft, Zithromax, and Norvasc.
• Profitability Decline: Net income decreased 18% primarily due to higher restructuring costs associated with the "Adapting to Scale" (AtS) productivity initiative ($969 million in Q1 2007 vs. $479 million in Q1 2006) and the absence of one-time tax benefits recorded in Q1 2006 ($658 million total).
• Cash Flow Reduction: Operating cash flow dropped significantly to $1.2 billion from $4.0 billion, largely due to higher tax payments ($1.8 billion increase) related to the gain on the sale of the Consumer Healthcare business and an increase in accounts receivable.
• Acquisitions: Pfizer recorded $283 million in acquisition-related in-process research and development charges related to the acquisitions of BioRexis Pharmaceutical Corp. and Embrex, Inc.

Guidance, Outlook, and Risks

• 2007 Forecast (Revised): Management forecasts full-year 2007 revenues of $47 billion to $48 billion. Reported diluted EPS is expected to be $1.30 to $1.41, while Adjusted diluted EPS is projected at $2.08 to $2.15. Cash flow from operations is expected to be $12 billion to $13 billion.
• 2008 Forecast: Revenues are forecast at $46.5 billion to $48.5 billion. Reported diluted EPS is expected to be $1.75 to $1.93, with Adjusted diluted EPS of $2.31 to $2.45.
• Productivity Initiative: The expanded AtS initiative aims to reduce the pre-tax total expense component of Adjusted income by $1.5 billion to $2.0 billion by the end of 2008 compared to 2006 levels.
• Key Risks:
  • Patent Expirations: Accelerated loss of U.S. exclusivity for Norvasc (March 2007) and uncertainty regarding Lipitor patent protection in Canada.
  • Legal Proceedings: Ongoing patent litigation regarding Lipitor, Norvasc, and Celebrex; settlements reached with the DOJ regarding former Pharmacia subsidiaries ($34.7 million in fines).
  • Regulatory: Pending FDA approvals for key pipeline products (e.g., Lyrica for fibromyalgia, Maraviroc for HIV).

Investor Verification Checklist

• Patent Litigation Outcomes: Monitor the status of appeals regarding Norvasc (U.S.) and Lipitor (Canada) patents, as these directly impact future revenue streams.
• AtS Cost Savings Realization: Verify if the projected $1.5 billion to $2.0 billion in expense reductions by 2008 are being achieved as planned.
• Lipitor Market Dynamics: Track prescription switch rates to generic simvastatin and the impact of new FDA indications on Lipitor's growth trajectory.
• Product Launch Performance: Assess the commercial uptake of new products like Exubera (inhaled insulin) and Chantix (smoking cessation) against management's expectations.
• Tax Position Resolution: Review updates on ongoing IRS audits and the impact of the new FIN 48 accounting standard on future tax provisions.